Alaunos Therapeutics' indibulin breast cancer trial terminated after Phase 1 only
The study closed enrollment following dose escalation, with no maximum tolerated dose reached and the planned Phase 2 portion never started.
ClinicalTrials.gov
Latest
Friday, October 2
Celcuity adds ex-Incyte, Celgene CFO David Gryska to board after REVTORPYK launch
The appointment, effective October 1, 2026, follows Celcuity's first FDA approval and the September 30 US launch of REVTORPYK for advanced breast cancer.
SEC filing (2)
FDA approves pirtobrutinib for untreated CLL or SLL
The approval covers adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who lack a 17p deletion.
FDA, Drugs@FDA (2)
Silo Pharma buys assets from Norsight Consulting in stock warrant deal
Silo Pharma issued a warrant for up to 300,000 shares to acquire software, technology and intellectual property from Norsight Consulting under an agreement dated October 1, 2026.
SEC filing
Lisata Therapeutics reports $351.9 million securities offering tied to business combination
A Form D filed October 2, 2026 shows Lisata sold the full offering to 20 investors with sales commissions of $2.6 million.
SEC filing
HCW Biologics files S-1 for resale of 1.8 million shares tied to September PIPE
The filing covers warrant shares from a $1.5 million financing and details Nasdaq compliance history and multiple unremediated internal control weaknesses.
SEC filing
Incyte registers two Phase 1 PK studies of INCB161734, in renal and hepatic impairment
Braveheart Bio's Phase 3 LIONHEART-HCM trial recruiting for BHB-1893 in oHCM
Cingulate extends CMO Matthew Brams' trial employment period to year-end 2026
A subsidiary of Cingulate Inc. amended its agreement with Chief Medical Officer Matthew N. Brams, pushing his trial employment deadline back three months.
SEC filing
Genentech gets two ROZLYTREK label updates; Roche's IMvigor011, forimtamig results stand
CNS Pharmaceuticals holds annual meeting, shareholders expand equity plan
Stockholders approved a 650,000-share increase to the company's 2020 Equity Plan and re-elected all six director nominees at the September 30, 2026 annual meeting.
SEC filing
Prothena's chief development officer to resign, join partner company
Chad J. Swanson, Ph.D. notified Prothena on October 2, 2026 that he is leaving effective October 9, 2026 to take a role at a strategic partner.
SEC filing
GSK registers three new Phase 3 trials spanning asthma, prostate cancer, ovarian cancer
Novartis registers new Phase IIIb IgAN trial and VEXAS Phase 2; gMG trial still active
Vanderbilt trial tests intrathecal cytarabine for ICANS after CAR T; Gilead is collaborator
Change Agents Corporation issues $336,000 in notes in second note tranche
The company raised $300,000 in gross proceeds through a new round of original issue discount notes and used the funds to pay down existing debt obligations.
SEC filing
OPKO Health says its 2029 convertible notes are now convertible through year-end
OPKO Health determined on October 1, 2026 that holders of its 3.75% Convertible Senior Notes due 2029 can convert through December 31, 2026, and said it will settle in common stock.
SEC filing
BeOne Medicines registers two Phase 1 hepatic impairment PK studies for sonrotoclax and tacabrutideg
Amneal recalls exenatide pens for empty-pen defect; also logs four labeling approvals
Boehringer Ingelheim registers five new trials, spanning oncology, obesity, and ILD screening
Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure results
AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adults
Sanofi posts SAR444881 results; adds two rilzabrutinib trials and RSV AI study
Biogen registers first-in-human trial of BIIB147 in ALS, called HORIZON
Lilly posts Phase 3 orforglipron results; registers new MDD trial and five other updates
Merck registers two new Phase 1/2 trials; KEYVIBE-005 results remain on record
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trial
AstraZeneca, Daiichi Sankyo, Summit to test Datroway with ivonescimab combo
The companies plan to start with a Phase III trial in first-line triple-negative breast cancer, per a filing dated October 2, 2026.
SEC filing
Addex names Jean-Philippe Rocher head of pharmaceutical development as Kalinichev departs
Rocher returns from Neurosterix retirement while Mikhail Kalinichev steps down to focus full time on his Neurosterix role.
SEC filing
Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world data
Evaxion to present new EVX-01 immune data at SITC 2026 meeting
Thursday, October 1
Evommune reports Phase 2a data for EVO301 in atopic dermatitis at EADV
The IL-18 inhibitor hit its primary endpoint at Week 12 and the company plans to start a Phase 2b subcutaneous trial in mid-2027.
SEC filing
BioCardia submits revised FDA pre-submission for Helix catheter
The company reported on October 1, 2026 that it filed an updated De Novo pre-submission with FDA's device center for its Helix catheter.
SEC filing
EMA validates PolyPid's marketing application for D-PLEX100
The European Medicines Agency's validation starts formal review of PolyPid's surgical infection prevention drug, which is also under FDA Priority Review with a November 28, 2026 PDUFA date.
SEC filing
Azitra clears safety review, moves ATR-04 trial to Cohort 2
The Phase 1/2 study of ATR04-484 for EGFR inhibitor-associated skin rash advances after a safety panel review of six Cohort 1 patients.
SEC filing
Gain Therapeutics reports 12-month open-label data for rexaceract in Parkinson's disease
Gain said MDS-UPDRS motor scores remained stable through a year of dosing, supporting plans for a Phase 2 trial in early 2027.
SEC filing
ENDRA and ASP Isotopes amend merger terms for Noble Africa deal
The October 1, 2026 amendment lifts a warrant ownership cap, de-classifies the planned board, and raises Renergen's borrowing room under an ASPI loan facility.
SEC filing
Vera Therapeutics posts ORIGIN 3 Phase 3 results for atacicept in IgA nephropathy
Arrowhead's SHASTA-10 extension study for plozasiran stays active, not recruiting
Opus KSD discloses $680,801 equity sale to 16 investors in Form D filing
The Pembroke, Massachusetts biotechnology firm reported a completed Regulation D offering with a first sale date of September 23, 2026.
SEC filing
TransCode pays down $840,975 to Yorkville after convertible notes breach floor price
TransCode made a prepayment to Yorkville to waive triggered amortization events after its stock traded below $1.72 for 10 of 14 trading days in September.
SEC filing
Akari Therapeutics amends CEO pay package for Abizer Gaslightwala
The company raised base salary, target bonus, and granted stock options tied to shareholder approval of an expanded equity plan.
SEC filing
Vir Biotechnology names Aziz Sawaf as new CFO effective October 5, 2026
Theravance Biopharma's former CFO takes over Vir's finance, IT and investor relations functions as Brent Sabatini steps down from interim duties.
SEC filing
Pelthos Therapeutics stockholders approve 2026 equity plan, re-elect full board
At its September 29, 2026 annual meeting, Pelthos shareholders elected eight directors, ratified Grant Thornton as auditor, and approved a new equity incentive plan.
SEC filing
Apimeds names Eric Sherb as CFO after Erick Frim resigns
The company disclosed on a Form 8-K that Frim stepped down as interim finance chief and Sherb will take over the role starting October 1, 2026.
SEC filing
Nanobiotix names Arnd Christ as new chief financial officer
Christ, former Immatics CFO, takes over October 1, 2026, replacing Bart Van Rhijn after his five-year tenure at the company.
SEC filing
MindWalk Holdings adds Kim Remizowski to board as independent director
The banking and fiduciary veteran will join the Audit Committee and the Compensation, Nomination and Governance Committee effective September 29, 2026.
SEC filing
Achieve Life Sciences names Benjamin Halladay as new CFO
Mark Oki departs as CFO effective October 5, 2026, with Benjamin Halladay stepping into the role the same day.
SEC filing
Aethlon Medical stockholders approve share plan increase and other proposals at annual meeting
At its October 1, 2026 annual meeting, Aethlon Medical stockholders approved ten proposals, including a 100,000-share increase to the 2020 Equity Incentive Plan and a boost to authorized common stock.
SEC filing
Pyxis Oncology closes $102.8 million public offering tied to MICVO data
The offering combines stock and warrants whose exercisability depends on a shareholder vote and the timing of a Phase 1 survival readout expected in the first half of 2027.
SEC filing